Favipiravir and Hydroxychloroquine Combination Therapy in Patients with Moderate to Severe COVID-19 (FACCT Trial): An Open-Label, Multicenter, Randomized, Controlled Trial

INTRODUCTION: Antiviral drugs have shown limited effectiveness in treating patients with coronavirus disease 2019 (COVID-19). We aimed to assess the effects of a favipiravir and hydroxychloroquine combination on treating moderate-to-severe COVID-19 patients. METHODS: An investigator-initiated, multi...

詳細記述

保存先:
書誌詳細
出版年:Infect Dis Ther
主要な著者: Bosaeed, Mohammad, Mahmoud, Ebrahim, Alharbi, Ahmad, Altayib, Hadeel, Albayat, Hawra, Alharbi, Faisal, Ghalilah, Khalid, Al Arfaj, Abdulmajid, AlJishi, Jumana, Alarfaj, Abdullatif, Alqahtani, Hajar, Almutairi, Badriah M., Almaghaslah, Manar, Alyahya, Nawaf M., Bawazir, Abdullah, AlEisa, Saud, Alsaedy, Abdulrahman, Bouchama, Abderrezak, Alharbi, Malak, AlShamrani, Majid, Al Johani, Sameera, Aljeraisy, Majed, Alzahrani, Mohammed, Althaqafi, Abdulhakeem O., Almarhabi, Hassan, Alotaibi, Athari, Alqahtani, Nasser, Arabi, Yaseen M., Aldibasi, Omar S., Alaskar, Ahmad
フォーマット: Artigo
言語:Inglês
出版事項: Springer Healthcare 2021
主題:
Original Research
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC8316887/
https://ncbi.nlm.nih.gov/pubmed/34319552
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40121-021-00496-6
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料